Dr. Verschraegen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Martha Morehouse Medical Pavilion
2050 Kenny Road, 4th Floor
Columbus, OH 43221Phone+1 614-293-4320Fax+1 614-293-2584- Is this information wrong?
Summary
- I am a professor of medicine and director of the Division of Medical Oncology in the Department of Internal Medicine at The Ohio State University College of Medicine. I also hold the Diane Nye and Michael Rayden Chair in Innovative Cancer Research at Ohio State and serve as associate director for translational research at Ohio State's Comprehensive Cancer Center.
I am a board-certified medical oncologist who specializes in treating patients with rare cancers, including mesothelioma, metastatic melanoma, sarcomas and gynecologic malignancies. Another of my specialties is the study of new anticancer drugs and treatments for solid tumors. My work has been continuously funded for more than 20 years, including grant support for phase I, II and III clinical trials. I have been appointed by the National Cancer Institute (NCI) to serve on many committees, such as the NCI Gynecological Cancer Steering Committee, which approves the federally-sponsored randomized studies for gynecological cancers.
I was recruited to Ohio State in 2017 from the University of Vermont, where I was a professor of medicine, director of Hematology/Oncology, director of the cancer service line and co-director of the University of Vermont Cancer Center. I earned my master's degree and medical degree at the Université Libre de Bruxelles in Belgium and trained at the Institut Jules Bordet in internal medicine/oncology. I then completed a cancer research fellowship at the Stehlin Foundation for Cancer Research and an internal medicine residency training at the University of Houston, followed by a medical oncology fellowship at The University of Texas MD Anderson Cancer Center.
In my 30 years as an academic medical oncologist, much progress has been made in treating some cancers through novel targeted therapies and immunotherapies, a result of the well-planned clinical and translational studies to which I have devoted the greatest part of my professional life. I am privileged to continue this mis
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1992 - 1994- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1988 - 1991
Universite Libre de Bruxelles Faculty of MedicineClass of 1982- Universite Libre de Bruxelles, School of BotanyM.S., Magna Cum Laude, 1977 - 1980
Certifications & Licensure
OH State Medical License 2017 - 2025
TX State Medical License 1993 - 2019
VT State Medical License 2011 - 2018
NM State Medical License 2002 - 2017
Awards, Honors, & Recognition
- Marquis Who's Who 2018
- US News & World Report 2015
- America's Top Doctors Castle Connolly, 2008-2014
- Join now to see all
Clinical Trials
- Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan Start of enrollment: 2003 Apr 01
- Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC) Start of enrollment: 2003 Apr 01
- Pharmacology Study of Aerosolized Liposomal 9-Nitro-20 (S)-Camptothecin (L9NC) Start of enrollment: 2003 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities.Jiang, Y., Ma, D., Jin, X., Xiao, Y., Yu, Y., Shi, J., Zhou, Y., Fu, T., Lin, C., Dai, L., Liu, C., Zhao, S., Su, G., Hou, W., Liu, Y., Chen, Q., Yang, J., Zhang, N., ...> ;Nature Cancer. 2024 Feb 12
- A Comprehensive Review of Immunotherapy Clinical Trials for Metastatic Urothelial Carcinoma: Immune Checkpoint Inhibitors Alone or in Combination, Novel Antibodies, Ce...Carrillo, A., Mortazavi, A., Patel, D., Mateen, R., Qaddour, N., Verschraegen, C., Yang, Y., Li, Z., Sundi, D., Collier, K.> ;Cancers. 2024 Jan 12
- Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies.Jason J Luke, Sarina A Piha-Paul, Theresa Medina, Claire F Verschraegen, Mary Varterasian, Aoife M Brennan, Richard J Riese, Anna Sokolovska, James Strauss, David L Ha...> ;Clinical Cancer Research. 2023 Jul 5
- Join now to see all
Journal Articles
- Hypofractioned radiation therapy for early breast cancer regional nodal irradiation - the jury is still outHilde Van Parijs, Nele Adriaenssens, Claire Verschraegen, Zineb Dahbi, Vincent Vinh-Hung, Guy Storme, Mark De Ridder, Nam P. Nguyen, Translational Cancer Research, 1/1/2018
- PEGylated engineered interleukin-2 (IL-2) CD122-biased immunostimulatory cytokine Cancer immunotherapyRogers, S.C., Shah, H., Yin, M., Folefac, E., Lee, R., Verschraegen, C., Drugs of the Future, 1/1/2018
- Management of high-grade pleomorphic sarcoma with colon metastasisConor O'Neill, MD, Jesse Moore, MD, Alexandra Kalof, MD, Carlos Marroquin, MD, Claire Verschraegen, MD, and Ted A James, MD, Journal of Community and Supportive Oncology, 1/1/2017
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Carboplatin and Pembrolizumab Chemoimmunotherapy Achieves Remission in Recurrent, Metastatic Sebaceous Carcinoma.Kodali S, Tipirneni E, Gibson PC, Cook D, Verschraegen C, Lane KA, Ophthalmic Plastic and Reconstructive Surgery, 1/3/2018
- Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial.Raffit Hassan, Anish Thomas, John J. Nemunaitis, Manish R. Patel, Jaafar Bennouna, Franklin Chen, Jean-Pierre Delord, Afshin Dowlati, Matthew H. Taylor, John D. Powder..., Journal of Clinical Oncology, 1/1/2018
- Incidence of ototoxicity in head and neck cancer (HNSCC) patients (pts) receiving concomitant chemo-radiation (CRT) with weekly or triweekly cisplatin (Cis).Jishu Das, Amy Custer, Dukagjin Blakaj, Matthew O. Old, Songzhu Zhao, Aashish D Bhatt, Stephan Y Kang, Amit Agrawal, Enver Ozer, Jessica Wobb, Robert Rupert, Darrion L..., J Clin Oncol, 1/1/2018
- Join now to see all
Lectures
- Growing Your Academic EnterpriseASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Consequences of CancerJames Cancer Hospital, Columbus, OH - 1/14/2018
- Overian CancerColumbus, OH - 1/5/2018
- Join now to see all
Other
- Peritoneal mesothelioma: Debulking or not?Verschraegen CF, Pro & Con Debate, Intraperitoneal Therapies Meeting
Lake Tahoe, NV - 1/19/2011 - Focus on Sarcoma.S Movva & C. Verschraegen, New Mexico Cancer Alliance Newsletter
1/1/2010 - Fall and Rise of the Vermont Cancer CenterVerschraegen CF, Burlington Free Press
http://archive.burlingtonfreepress.com/article/20121001/NEWS02/310010006/The-fall-and-rise-of-the-Vermont-Cancer-Center
1/1/2002 - Join now to see all
Authored Content
- Focus on Ewing Sarcoma – Time for a Change in the Standards of Care?June 2022
Press Mentions
FDA Approves Biosimilar Bevacizumab-Adcd for the Treatment of Six Types of CancerSeptember 30th, 2022
Shop TalkAugust 10th, 2017
Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLCJanuary 11th, 2017- Join now to see all
Professional Memberships
- Member
- Member
- Member
Other Languages
- French, Spanish
Hospital Affiliations
The OSUCCC - JamesColumbus, Ohio
Ohio State University Wexner Medical CenterColumbus, Ohio
Industry Relationships
- Director, The Ohio State University Comprehensive Cancer CenterDirector of the Division of Medical Oncology2017 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
